

Formulary Update

January 2024

The following changes to the [Adult Medicines Formulary](#) have been agreed during the ADTC or sub-committee meetings since November 2023. Additions and deletions of medicines are based on submitted formulary appeals, new drug assessment requests or formulary section reviews. Changes in preferred brands are based on decisions by Prescribing Management Groups.

ADTC decisions relating to SMC assessments are published in alternate months and can be accessed [here](#)

Deletions	Indication	Adult Medicines Formulary entry/ rationale	
Monophasic standard-strength combined oral contraceptives	Ovranette removed	7.3.1	Primary care guideline and formulary section review
Additions	Indication	Adult Medicines Formulary entry/ rationale	
Anthelios Factor 50+ sunscreen	Added as a Preferred List option. ACBS restrictions apply to prescribing.	13.8.1	New drug assessment
Changes in preferred medicines or brand	New preferred medicines or brand	Adult Medicines Formulary entry / rationale	
Low strength combined oral contraceptives	Bimizza 20/150 replacing Gedarel 20/150 Akizza 20/75 replacing Millinette 20/75	7.3.1	Primary care guideline and formulary section review
Standard strength combined oral contraceptives	Levest added and now 1 st line option Rigevidon 1 st line status removed	7.3.1	Primary care guideline and formulary section review
Ulipristal acetate	Preferred 1 st line option for emergency contraception	7.3.5	Formulary appeal
Other changes	Changes made	Adult Medicines Formulary entry/ rationale	
Pivmecillinam	Prescribing notes added clarifying starting and continuation criteria	5.1.1	Antimicrobial Utilisation subcommittee advice
Quinolone antibiotics	New MHRA advice (January 2024) on further restricted use updated in formulary entries for ciprofloxacin, levofloxacin, moxifloxacin, ofloxacin, delafloxacin.	5.1.12	MHRA advice
Sodium valproate	Latest MHRA guidance (January 2024) updated in formulary entry.	4.8.1	MHRA guidance
Levonorgestrel (emergency contraception)	Upostelle removed as preferred brand in NHSGGC.	7.3.5	Primary care guideline and formulary section review